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List of abbreviations: ASCA: anti-Saccharomyces cerevisiae antibody, AZA: 
azathioprine, BT: bacterial translocation, CD: Crohn’s disease, CRP: C-reactive 
protein, ECCO: European Crohn’s and Colitis Organisation, EIM: extraintestinal 
manifestations, ELISA: enzyme-linked immunosorbent assay, HBI: Harvey–
Bradshaw Index, HR: hazards ratio, IBD: inflammatory bowel diseases, Ig: 
immunoglobulin, IQR: inter quartile range, LPS: lipopolysaccharide, PSC: primary 
sclerosing cholangitis, UC: ulcerative colitis, 95%CI: 95% confidence interval, TNF: 
tumor necrosis factor  
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ABSTRACT 
Background: Early identification of patients with Crohn’s disease (CD) at risk for 
subsequent complications is essential for adapting treatment strategy. We aimed to 
develop a prediction model including clinical and serologic markers for assessing the 
probability of developing advanced disease in a prospective referral CD cohort. 
Patient and methods: 271 consecutive CD patients (42.4% males, median follow-up: 
108 months) were included and followed-up prospectively. Anti-Saccharomyces 
cerevisiae antibodies (ASCA IgA/IgG) antibodies were determined by enzyme-linked 
immunosorbent assay (ELISA). The final analysis was limited to patients with 
inflammatory disease behaviour at diagnosis. The final definition for advanced 
disease outcome was having intestinal resection or disease behaviour progression. 
Results: ASCA (IgA and/or IgG) status, disease location, and need for early 
azathioprine (AZA) were included in a 3-, 5- and 7-year prediction matrix. The 
probabilities of advanced disease after 5-years varied from 6.2% to 55% depending on 
the combination of predictors. Similar findings were obtained in Kaplan-Meier 
analysis, the combination of ASCA, location and early use for AZA was associated 
with the probability to develop advanced disease (pLogRank<0.001). 
Conclusion: Our prediction models identified substantial differences in the 
probability of developing advanced disease in the early disease course of CD. 
Markers identified in this referral cohort were different from those previously 
published in a population-based cohort suggesting that different prediction models 
should be used in referral setting. 
 
Word count 222 
Key words: serologic antibodies, ASCA, Crohn’s disease, disease progression, 
referral cohort, azathioprine 
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INTRODUCTION 
Crohn’s disease (CD) is a multifactorial chronic inflammatory disease of the 
gastrointestinal tract. It runs a variable disease course, yet the majority of patients 
eventually develop penetrating or stricturing complications leading to repeated 
surgeries and disability 1.  
Studies on the natural history of CD provide important data on its course and 
may help to identify clinical predictors for disease progression. Some years ago, 
Peyrin-Biroulet et al. published a systematic review of the natural history of CD in 
population based-cohorts2 and concluded that available data did not suggest a 
significant change in disease course, with approximately half of patients requiring 
surgery within 10 years after the diagnosis. Furthermore, the authors stated that the 
impact of changes in monitoring and treatment paradigms with increased and earlier 
use of immunosuppressants and biological agents on the natural history of the disease 
was poorly understood.  
Interestingly, an increasing proportion of patients were diagnosed with 
uncomplicated disease behaviour in recent population-based cohorts; e.g. in a study 
from New Zealand 3. >70% of CD patients had inflammatory disease at diagnosis, 
while only 23% and 40% of those progressed to complicated disease after 5- and 10 
years after the diagnosis, respectively. Similarly, the rate of initial inflammatory 
disease behaviour was as high as 68% and 75% in CD patients from Western and 
Eastern Europe in the most recent EpiCom study 4 with only 10% of all patients 
presenting with perianal involvement.  
Therefore, early stratification of patients became utmost important to avoid 
negative outcomes and considerable emphasis has been placed in recent years on the 
determination of important predictive factors. In one of the early approaches, an 
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initial need for steroid use, an age below 40 years and the presence of perianal disease 
were associated with the development of disabling disease in the landmark paper by 
Beaugerie et al.
5. However, the definition of disabling outcome was complex and 
included the need to start immunosuppressives. Multiple studies reported a more rapid 
progression towards complicated disease in CD patients with small bowel or perianal 
disease 3, 6 . In another Belgian study besides perianal lesions, the early need for 
steroids and ileo-colonic location, but not age below 40 years were identified as 
predictive markers for the development of disabling disease (according to the 
predefined criteria) at 5 years 7. In addition, according to available data pediatric-
onset CD runs a more aggressive course, with more extensive disease location, more 
upper gastrointestinal involvement, more active disease, growth failure, and need for 
more aggressive medical therapy in predominantly referral-center studies 8-10 with 
some exceptions 11. 
Recently, the IBSEN group 12 has developed a population-based risk 
assessment model based on complex evaluation of clinical (age at onset, location and 
early steroid requirement) and serologic (anti-Saccharomyces cerevisiae antibody 
[ASCA] positivity) variables that was able to predict the risk of disease outcome 5- 
and 10 years after the diagnosis. However, similarly to the previous French 5 approach 
need for immunosuppressants was defined as adverse outcome. In contrast, in an 
earlier study by our group, early aggressive immunosuppressive therapy was 
associated with a reduction in surgical rates in a population-based study 13 from 
Hungary even after fitting the model on propensity scores. Almost certainly, future 
complex prediction models should assess the value of early aggressive treatment 
strategy as a possible predictor of disease progression. 
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Early identification of CD patients at risk for subsequent complications is 
essential for adapting treatment strategy in the everyday clinical practice, especially in 
CD patients followed-up in referral IBD centers. Therefore, the aim of the present 
study was to develop a prediction model including clinical and serologic markers for 
assessing the probability of developing advanced disease during medium-term follow-
up in a prospective referral CD cohort. 
 
MATERIAL AND METHODS 
 
Patient population 
A total of 271 well-characterized, unrelated, consecutive CD patients with a complete 
clinical follow-up (male/female: 120/140, median age at presentation: 25 years (inter 
quartile range [IQR], 19-33) seen in one tertiary IBD referral center of Hungary 
(Department of Gastroenterology, Institute of Internal Medicine, University of 
Debrecen) were included between January 1, 2005 and June 1, 2010 and were 
followed-up until October 1, 2013.  Blood samples and detailed clinical phenotypes 
were captured at inclusion. 
The clinical characteristics of the patients at diagnosis are presented in Table 
1. Diagnosis of IBD was based on the Lennard–Jones criteria 14. The disease 
phenotype (age at onset, duration, location, and behaviour) was determined according 
to the Montreal Classification 15. Blood samples and detailed clinical phenotypes were 
captured at inclusion. Clinical data were determined by thorough review of patients’ 
medical records, which had been collected in a uniform format. Medical records that 
documented the disease phenotype, presence of extraintestinal manifestations (EIM) 
(for example, arthritis: peripheral and axial; ocular manifestations: conjunctivitis, 
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uveitis, iridocyclitis; skin lesions: erythema nodosum, pyoderma gangrenosum; and 
hepatic manifestations: primary sclerosing cholangitis [PSC]), frequency of flare-ups 
(frequent flare-up: >1 clinical relapse/year) 16, medication use (e.g., steroid, 
immunosuppressive and/or biological use at any time), need for surgery (resections), 
the presence of familial IBD, smoking habits, and perianal involvement were 
retrospectively analysed for the period prior to the prospective follow-up and 
prospectively thereafter.  
 
In Hungary, a follow-up visit is usually scheduled for every 6 months at a specialized 
gastroenterology center (the actual interval varies between 3–6 months). In addition, a 
harmonized, mandatory, tight monitoring strategy is requested and regularly 
controlled by the National Health Fund (OEP) in anti-TNF exposed patients including 
CDAI-PDAI assessment, laboratory evaluation (including CRP) at least every 3 
months and endoscopy/imaging at least every 12 months. The start of 
immunosupressive or anti-TNFs was indicated by the same 3 IBD specialists 
throughout the study period by using the ECCO guidelines, the center’s treatment 
policy and prescription regulations. Follow-up was terminated if there was no further 
record available. Median follow-up from diagnosis was 108 months (IQR, 65-178).  
Definitions of advanced disease 
Two definitions were used for advanced disease: 1. having intestinal resection or 
progression in disease behaviour and 2. having intestinal resection, progression in 
disease behaviour, or need for thiopurines (IBSEN definition). Early AZA need was 
defined as need of AZA within 3 years from the diagnosis. 
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Serological Analysis 
Blood samples were obtained at enrolment from each patient and were frozen at -80℃ 
until testing. All the serological assays were performed in a blinded fashion without 
prior knowledge of the patients’ diagnosis or other clinical information. In 40.2% of 
the patients the sampling was done at early stages of the disease (duration of disease 
less than two years) and in 59.8% of patients with >2 years disease duration. The 
overall disease duration at sampling was 3 years (median [IQR]: 0-8 years). 
 
Detection of anti-microbial antibodies  
The presence of anti-Saccharomyces cerevisiae antibodies (ASCA) IgA, ASCA IgG 
in serum was determined by enzyme-linked immunosorbent assay (ELISA) 
(QUANTA LiteTM, INOVA Diagnostics, San Diego, CA) according to the 
manufacturers’ instructions. The results are presented as arbitrary units, and values 
above the cut-off of 25 units were considered as positive. The results were 
documented in absolute values and in frequency of positivity.  
All the serologic assays were performed in a blinded fashion without prior 
knowledge of the patients’ diagnosis or other clinical information.  
 
Ethical considerations 
The regional and national committee [DEOEC RKEB/IKEB 3515-2011, 
3880/2012/EKU (59/PI/2012)] for research ethics approved the study protocol. Each 
patient was informed of the nature of the study and signed an informed consent form. 
 
Statistical analysis 
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Continuous variables were summarized as medians [interquartile range (IQR)] 
according to their homogeneity. The predictive potential of the different models for 
predicting advanced outcome according to the 2 pre-set definitions were tested by 
both cross sectional analysis after pre-set time-points at 3-, 5- and 7 years after the 
diagnosis and also in time-dependent models. We developed two different models. In 
the first model we replicated matrix model with the original variables and outcome 
definition reported by the IBSEN group 12 in our referral cohort both after the pre-set 
time-points and in the time-dependent model. However, because of limited number of 
cases we limited the final model to the combination of 3 variables. This was based on 
the result from the univariate chi-square tests where age at diagnosis was not 
significant. In the second step, since the predictive potential was better by grouping 
the location as colon only vs. ileal involvement (padvanced disease for L2 vs. other=0.002), we 
repeated the testing after changing the location grouping. In addition, our group has 
shown that early AZA therapy is rather a treatment decision than a negative outcome 
and may predict surgical outcome in the population-based setting 13 and early AZA 
need in the present study was associated with advanced disease in every model. 
Therefore, in the third step, we developed a new model and analysed the outcomes 
after substituting early steroid requirement by early AZA requirement and used a 
modified advanced disease definition (excluding the need for AZA). In addition,  the 
association between possible risk factors and the modified advanced 5-year outcome 
definition were assessed in both univariate and multivariate logistic regression testing. 
Variables with a p<0.2 were selected for multiple testing 17. In addition, Kaplan-Meier 
survival curves were plotted for analysing the association between the combination of 
clinical variables, serological antibodies and complicated disease outcomes during 
follow-up with LogRank test. A 2-sided probability value < 0.05 was considered to be 
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statistically significant. For statistical analysis, GraphPadPrism 6 (San Diego, CA) 
and SPSS 20.0 (SPSS Inc, Chicago, IL) programs were used. 
 
RESULTS 
At diagnosis, 79.7% of the CD patients had inflammatory behaviour and 45% had 
ileocolonic disease (see Table 1). Disease progression during follow-up was 
significant with 52% of the patients progressing to complicated disease behaviour and 
41.1% of the patients had at least one resective surgery at last follow-up. Total 
exposures to steroids, AZA or anti-TNFs were 88.2%, 73.8% and 41.7%, 
respectively.  
 
Predicting advanced disease during follow-up in referral CD patients with non-
stricturing and non-penetrating disease behavior at diagnosis 
 
The association between clinical and serologic variables and advanced outcome at 3-, 
5- and 7 years by either the original definition or the modified definition is 
summarized in Table 2. Location (colon vs. ileal involvement), early AZA need and 
ASCA positivity were identified as independent predictors for advanced outcome. 
The original model including ASCA (IgA and/or IgG), disease location, and early 
need for steroids but not age at onset, was of low discriminative potential to predict 
advanced outcome in this referral CD cohort at 5 years if the original definition was 
used (Table 3). In addition, a lack of separation among the groups was observed in 
the time-dependent model (Figure 1, p=NS for ASCA positive vs negative 
subgroups).  
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The predictive potential was not much better if the need for AZA was excluded from 
the advanced disease definition (data not shown). 
 
The predictive potential of the model was not much better after changing the location 
grouping both with the original definition (Table 4) and with the modified definition 
of advanced outcome after excluding need for AZA from the advanced outcome 
definition (data not shown). 
 
The combination of ASCA (IgA and IgG) status, disease location, and need for early 
AZA was associated with advanced outcome by using the modified definition of 
advanced disease (need for surgery and disease behaviour change). The probabilities 
of advanced disease 5 years after diagnosis varied from 6.2% to 55% depending on 
the combination of predictors (Table 5). The 3- and 7-year ASCA-based model 
resulted in probabilities of advanced disease ranging from 0% to 45.5% and from 
11.1% to 64.7%. Similar findings were obtained Kaplan-Meier analysis, where the 
combination of ASCA, location and early AZA was associated with the probability to 
develop advanced disease (pLogRank<0.001, Figure 2.), 
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 DISCUSSION 
The present study has shown that the disease course may be predicted in referral CD 
patients in a complex model including disease phenotype, serologic and treatment 
variables. We have also confirmed that different models are necessary for the 
prediction of disease outcomes in referral CD cohorts with different predictors 
compared to the population-based setting. 
 The risk factors – location, ASCA, early steroid requirement and early 
azathioprine therapy – identified for developing disease complication (in the present 
study the final definition was a change in disease behaviour or surgery) in patients 
with initial uncomplicated disease were in line with factors identified published from 
previous population-based 3, 12, 13 or referral cohort 5-7, 18 studies. Of note, however, 
there is a significant variance in the definition of adverse outcome in the published 
literature. In the French study 5, performed in a tertiary referral center in 1123 
patients, adverse outcome was defined as fulfilling at least one of the following 
criteria within the first 5 years after the diagnosis: the need for more than 2 steroid 
courses or steroid dependency, the need for immunosuppressive treatment, disabling 
chronic symptoms, hospitalization, or surgery. Using this definition, 3 risk factors at 
diagnosis were found to be independently associated with a disabling 5-year course of 
disease: age < 40-years, presence of perianal disease, and requirement for steroids. 
However, the clinical importance of these factors is clearly different, and there is little 
doubt that the start of immunosuppressive therapy rather represents a treatment 
strategy decision than a negative outcome. However the discriminative potential of 
the model was low, as the chance for disabling outcome in this referral CD cohort was 
approximately 90% in the first 5 years of the disease.  
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In a Belgian referral cohort study, ileo-colonic location, perianal lesions and 
the need for steroids for the first flare, but not age below 40 years were identified as 
predictive markers for developing disabling disease at 5 years 7. In the same study, 
stricturing behavior and weight loss at diagnosis were independently associated with 
the time to development of severe disease. However, the definition of adverse 
outcome was different. The authors focused on more objective factors and the 
definition included the presence of at least one of the following criteria: the 
development of a complex perianal disease, any colonic resection, two or more small-
bowel resections (or a single small bowel resection measuring more than 50 cm in 
length) or the construction of a definite stoma. Similarly, perianal disease, small 
bowel disease, smoking, prior steroid use, early AZA or AZA/biological therapy are 
all predictors of disease behavior change in our previous referral CD cohort study 6. 
Furthermore, progression towards complicated disease was also more rapid in those 
with small bowel compared to colonic disease (p<0.001) in a New Zealand cohort 3, 
and perianal disease was a significant predictor of change in CD behavior (HR: 1.62, 
p<0.001). Thus, patients with small bowel involvement should be observed especially 
closely.  
In addition, biomarkers including serologic markers, especially ASCA, were 
linked to complicated disease behaviour and CD-related surgery in previous referral 
CD cohorts and in a meta-analysis 18-20. Furthermore, in CD, but not in UC, they have 
also been associated with prediction of aggressive disease phenotype and a faster 
progression towards complicated disease, need for surgery 21.  
Finally, treatment strategy has also changed in the last decade. Monitoring 
became tighter together with earlier introduction of immunomodulator therapy. 
Relatively recent population-based reports from Wales and Hungary 22reported that 
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early AZA use may be associated with reduced need for resective surgery and delayed 
the time to first operation in a population-based CD cohort after matching on 
propensity scores in the later study. Although, two recent controlled trials from the 
French and Spanish IBD groups 23, 24 investigating the clinical benefit of systematic 
early introduction of AZA failed to show a short term benefit on symptomatic relapse 
and clinical remission rates even though the need for perianal surgery was lower (4% 
versus 18%, p=0.036) in the study by the GETAID group. Thus whether azathioprine 
has the potential for disease modification in early CD remains controversial. 
Interestingly, in the present referral cohort, early AZA use was not preventive for 
advanced outcome in initially B1 patients. Of note however, this reflects at least 
partly the differences in the cohort setting, and a high percentage of patients in the 
present referral cohort were treated with anti-TNFs. 
In the present study we wanted to exclude patients with an already 
complicated disease and focused on identifying possible risk factors for advanced 
disease in the subgroup of patients with non-complicated disease behaviour (B1) at 
diagnosis. In previous studies, the probability of developing complications in CD was 
reported the highest during the first years after diagnosis 3,5,6. Furthermore, there is a 
window of opportunity in CD and clinical outcomes were better with early aggressive 
therapy in the first years of the disease 25,26. Therefore, we focused on the first 3-7 
years of the disease in the prediction models. During this period, 30.4%, 42.8% and 
52% of B1 patients developed advanced disease at 3-, 5- and 7 years according to the 
modified definition (disease behaviour change or need for resective surgery). 
Although a direct comparison with the IBSEN cohort12 should be interpreted with 
caution, a much lower proportion of the patients, app.  36% developed advanced 
outcome after 5 years according to the original definition including the need for 
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immunosuppressives in the definition. The rate of advanced disease according to this 
definition was 64.5% at 5 years in this referral cohort, which reflects at least partly the 
different cohort setting and inherent higher disease progression rates in a referral 
setting. Of note, the probability of developing advanced disease during the first 5 
years using the modified criteria ranged from 6.2% to 55.5% in the final model 
depending on number of positive risk factors demonstrating a good discriminative 
potential of the tool to assess future risk of developing advanced disease in a given 
patient based on a given risk factor profile shortly after diagnosis.  
The authors are aware of possible limitations of the present study. Serological 
markers were not measured in each patient at the time of the diagnosis although 
stability of these markers has been previously demonstrated 27. Patient management in 
CD has changed significantly in the last decade including tight monitoring quicker 
access to imaging (e.g. availability of CT and MRI), increased and earlier access to 
anti-TNFs and also surgery techniques especially in referral centers that could have 
potentially affected the probability of developing advanced outcomes and surgery 
rates in CD.  Therefore, results from our study may not be generalized to patient 
cohorts outside IBD centers and with a more limited access to biological therapies and 
less stringent patient monitoring. In contrast, the strengths of the study include tight 
uniform patient monitoring and the use of a more straightforward definition advanced 
disease outcome including only high impact clinical scenarios. In addition, the access 
to biological therapy in Hungary is one of the best in Middle-Eastern Europe currently 
with more than 2500 IBD patients on anti-TNF therapy equaling app 9% in CD28. A 
harmonized, mandatory, tight monitoring strategy is requested and regularly 
controlled by the National Health Fund (OEP) in anti-TNF exposed patients including 
CDAI-PDAI assessment, laboratory evaluation (including CRP) at least every 3 
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months and endoscopy/imaging at least every 12 months. Furthermore, biological 
therapy is centralized in Hungary to 16 high volume IBD centers that serve as tertiary 
referral centers for IBD and the exposure of anti-TNFs in these centers is high, app. 
40%29. Thus we believe that our cohort is representative to high volume IBD centers 
from other parts of the world applying an early aggressive treatment and tight 
monitoring strategy and after validation from an independent cohort from another 
geographic region results may be generalized to this setting. Finally, the decision to 
start AZA and anti-TNFs were uniform and IBD specialists in the center followed the 
European, Hungarian guidelines and prescription regulations.  
In summary our prediction models identified significant differences in the 
probability of developing advanced disease in the short and intermediate course of 
CD. The „referral” risk matrix model included ASCA IgA and/or IgG, disease 
location, and need for early AZA use. Markers identified in this referral cohort were 
different from those previously published in the population-based cohort suggesting 
that different prediction models should be used for patients in referral setting. 
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FIGURE LEGENDS 
 
Figure 1. Probability of developing of advanced disease outcome according to the 
original definition in referral CD patients with non-stricturing and non-penetrating 
disease behavior (B1) at diagnosis.  
 
 
Figure 2. Probability of developing of advanced disease outcome according to the 
modified definition in the referral CD cohort in patients with non-stricturing and non-
penetrating disease behaviour (B1) at diagnosis. 
Page 23 of 34
https://mc.manuscriptcentral.com/ecco-jcc
Manuscripts submitted to Journal of Crohn's and Colitis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Lakatos PL Risk matrix in CD 24
TABLES 
Table 1. Clinical characteristics of the referral cohort with Crohn’s disease (CD). 
 
Table 2. Association between clinical, serologic variables and advanced disease 
outcome after 3-, 5- and 7 years after the diagnosis according to the different outcome 
definitions. 
 
Table 3. Risk matrix showing advanced 5-year outcome according to the original 
definition 1 in referral CD patients with non-stricturing and non-penetrating disease 
behaviour (B1) at diagnosis. 
 
Table 4. Risk matrix showing advanced 5-year outcome according to the original 
definition in referral CD patients with non-stricturing and non-penetrating disease 
behavior (B1) at diagnosis after changing the location grouping.   
 
 
Table 5. Association between ASCA IgA and IgG positivity, disease location and 
need for early azathioprine (AZA) with the probability of developing advanced 
disease outcome 5-years according to the modified definition 1 after the diagnosis in 
referral CD patients with non-stricturing and non-penetrating (B1) disease behavior at 
diagnosis. 
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Table 1. Clinical characteristics of the referral cohort with Crohn’s disease (CD).  
 
 CD patients 
N=271 
Males/females 42.4% / 47.6% 
Median follow-up (IQR), months 108 (65-178) 
Inflammatory behaviour at diagnosis 79.7%  
Ileocolonic disease at diagnosis 45.0% 
Complicated disease behaviour at last follow-up 52.0% 
At least one resective surgery at last follow-up 41.1%  
Total steroid exposure 88.2% 
Total azathioprine exposure 73.8% 
Total anti-TNF exposure 41.7% 
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Table 2. Association between clinical, serologic variables and advanced disease outcome after 3-, 5- and 7 years after the diagnosis according to 
the different outcome definitions. 
 IBSEN  
advanced  
disease 
outcome
1 
at 5 years 
 advanced  
disease 
outcome
2 
at 3 years 
 advanced  
disease 
outcome
2 
at 7 years 
 advanced  
disease 
outcome
2 
at 5 years 
univariate 
 advanced  
disease 
outcome
2 
at 5 years  
 
 p value OR (95% 
Cl) 
p value OR 
(95%Cl) 
p value OR 
(95%Cl) 
univariate 
p value 
OR 
(95%Cl) 
mulivariate 
p value 
OR 
(95%Cl) 
Gender 0.41  0.20  0.29  0.24  -  
Age at 
onset 
0.42  0.15  0.34  0.25  -  
Location 
IBSEN 
(colon 
and 
ileocolon) 
0.71  0.48  0.03 0.44 
(0.20-
0.92) 
0.21  -  
Location 
colon only 
vs. ileal 
involveme
nt 
0.002 0.42 
(0.24-
0.74) 
<0.001 0.26 
(0.13-
0.50) 
<0.001 0.28 
(0.15-
0.53) 
<0.001 0.27 
(0.14-
0.49) 
<0.001 0.29 
(0.15-
0.55) 
Early 
steroid
3
 
0.001 3.41 
(1.59-
7.29) 
0.19  0.99  0.42  -  
Early 
AZA
4
 
*  <0.001 3.30 
(1.92-
0.002 2.50 
(1.41-
<0.001 2.64 
(1.54-
0.001 2.62 
(1.46-
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5.64) 1.91) 4.52) 4.67) 
total AZA *  0.004 2.64 
(1.33-
5.24) 
0.31  0.13  -  
ASCA 
either 
0.001 2.65 
(1.48-
4.76) 
<0.001 3.44 
(1.81-
6.56) 
0.002 2.66 
(1.40-5.07 
0.001 2.74 
(1.47-
5.11) 
0.04 2.03 
(1.03-
3.96) 
ASCA 
both 
0.005 2.23 
(1.27-
3.92) 
<0.001 2.88 
(1.69-4.91 
<0.001 2.87 
(1.62-
5.07) 
<0.001 3.02 
(1.75-
5.20) 
0.002 2.52 
(1.42-
4.49) 
Smoking 0.31  0.15  0.85  0.25  -  
1 Having intestinal resection, progression in disease behaviour, or need for thiopurines  (IBSEN definition) 
2 Having intestinal resection or progression in disease behaviour 
3 Early steroid needs was defined as need of steroid within 30 days from the diagnosis 
4 Early AZA need was defined as need of AZA within 3-years from the diagnosis 
* AZA is included in the advanced outcome definition by the IBSEN group 
AZA: azathioprine
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Table 3. Risk matrix showing advanced 5-year outcome according to the original 
definition 1 in referral CD patients with non-stricturing and non-penetrating disease 
behaviour (B1) at diagnosis. 
 
ASCA  
(IgA and/or IgG) 
Early steroid* 
requirement 
Colon location at 
diagnosis (L2+L3) 
Ileal or upper GI 
location  (L1+L4) 
ASCA Positive 
YES 72.5% 66.7% 
NO 50.0% 53.3% 
ASCA Negative 
YES 69.6% 75.0% 
NO 16.7% 30.0% 
*within 30 days from diagnosis 
1 Having intestinal resection, progression in disease behaviour, or need for 
thiopurines  (IBSEN definition) 
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Table 4. Risk matrix showing advanced 5-year outcome according to the original 
definition in referral CD patients with non-stricturing and non-penetrating disease 
behavior (B1) at diagnosis after changing the location grouping.   
   
ASCA either 
(IgA or IgG) 
Early steroid* 
requirement 
Only colon location 
at diagnosis (L2+L3) 
Ileal location at 
diagnosis (L1+ L4) 
ASCA Positive 
YES 58.3% 80.0% 
NO 63.6% 58.3% 
ASCA Negative 
YES 73.7% 70.4% 
NO 22.6% 26.1% 
*within 30 days from diagnosis 
1Having intestinal resection, progression in disease behaviour, or need for 
thiopurines  (IBSEN definition) 
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Table 5. Association between ASCA IgA and IgG positivity, disease location and 
need for early azathioprine (AZA) with the probability of developing advanced 
disease outcome at 5 years according to the modified definition 1 after the diagnosis in 
referral CD patients with non-stricturing and non-penetrating (B1) disease behavior at 
diagnosis. 
 
ASCA  
(IgA and IgG) 
Early AZA* 
requirement 
Only colon location 
at diagnosis (L2) 
Ileal location at 
diagnosis (L1, L3, L4) 
ASCA Positive 
YES 50.0% 55.0% 
NO 30.8% 29.0% 
ASCA Negative 
YES 11.1% 22.2% 
NO 6.2% 18.8% 
*Early AZA need was defined as need of AZA within 3-years from the diagnosis  
1 need for surgery and disease behaviour change 
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FIGURES 
 
Figure 1. Probability of developing of advanced disease outcome according to the 
original definition in referral CD patients with non-stricturing and non-penetrating 
disease behavior (B1) at diagnosis.  
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Figure 2. Probability of developing of advanced disease outcome according to the 
modified definition in the referral CD cohort in patients with non-stricturing and non-
penetrating disease behaviour (B1) at diagnosis. 
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